24 biotech startups that are poised to take off

Hello,

Welcome to Insider Healthcare. I'm Lydia Ramsey Pflanzer, and today in healthcare news:

• The 24 biotech startups VCs say will take off in the next year;
• Flawed ideas about testosterone are fueling Republican bills to ban trans kids in sports;
• Your COVID-19 vaccine isn't perfect.

If you're new to this newsletter, sign up here. Comments, tips? Email me at lramsey@insider.com or tweet @lydiaramsey125. Let's get to it...

Meet the 24 biotech startups that top VCs say are poised to take off in the next 12 months

• Insider asked 12 top VCs to name biotech startups poised to take off in the next 12 months.
• Here are the 24 startups they named and what each biotech is working on.
• They are revolutionizing manufacturing, bringing tech into the lab, and developing innovative drugs.

Get the full list>>

Republicans want to prevent future Olympians like Laurel Hubbard - so they're banning trans kids from school sports

• Many anti-trans bills that lawmakers are voting on aim to ban trans kids in school sports.
• There is no evidence that trans women's testosterone levels give them an advantage over their cis competitors.
• On an elite level, trans athletes are underrepresented.

Read the full feature>>

Think of your COVID-19 vaccine as a seatbelt, not impenetrable armor

• COVID-19 vaccines aren't perfect, and you can still get sick after you have all your shots.
• But a vaccinated person's infection will likely be milder, because their body has built up its defenses.
• Vaccines are a lot like seatbelts: they save lives, but they can't prevent crashes.

Find the full analysis here>>

More stories we're reading:

• VCs name the top 15 startups in the psychedelics industry (Insider)
• We're realizing COVID-19 will be around for a while, and it's leading to anger and denial (Stat News)
• Surgeon general says he's 'deeply concerned' as COVID-19 cases reach record highs in Florida (Insider)
• COVAX is running into issues getting shots administered as Delta spreads (The New York Times)

- Lydia